A major step forward in the early diagnosis of cardiovascular diseases: The high-sensitivity cardiac troponin I (hs-cTnI) test is revolutionising this field. SHD Test is pioneering this innovation by contributing not only to clinical results but also to academic research.
Clinical Accuracy and Reliability
Troponin I protein is one of the most reliable biomarkers for detecting cardiac muscle damage. SHD Test’s hs-cTnI solution is accurate even at very low levels of 5 pg/ml. This enables early diagnosis as well as rapid detection of even less obvious cases. This high accuracy reduces false negative rates, especially in low-risk patients.
New Approaches in Diagnostic Technology
The devices offered by SHD Test stand out with their high sensitivity as well as their portability and fast result capability. These features are particularly suitable for use in intensive care units, emergency services and mobile health platforms. The widespread use of high-sensitivity testing ensures more consistent clinical results and helps to make faster and more informed decisions in patient management.
Scientific Collaborations and Expanding Opportunities
SHD Test aims to support innovative projects in the academic world. To this end, it offers hs-cTnI tests free of charge for use in research projects. This enables the development of new diagnostic protocols and independent validation of existing approaches. Thus, while contributing to the academic literature, gaps in clinical practice are also filled.
Personalised Medicine and POCT Trends
In the healthcare sector, personalised medicine and portable diagnostic devices (POCT) are becoming increasingly important. hs-cTnI tests epitomise this trend, increasing patient satisfaction and improving the efficiency of healthcare systems. SHD Test’s technology not only meets these demands, but also contributes to the establishment of new diagnostic standards.
Steps for the Future
The hs-cTnI test not only improves current diagnostic methods, but also lays the foundation for future healthcare innovations. We invite the academic and clinical communities to explore and develop these innovations. Please contact us for further information and collaboration opportunities.